Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: SAGE-Seq gene expression profiles of Hs578T, MCF7, and SUM159PT cells treated with STAT3 or non-targeting siRNAs, DMSO, or CXCR2, PTGIS, HAS1, PFKFB3, JAK, or NQO1 inhibitor

PROVIDER: PRJNA127973 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR060885.fastq.gz	Fastqsanger.gz
	SRR060886.fastq.gz	Fastqsanger.gz
	SRR060887.fastq.gz	Fastqsanger.gz
	SRR060888.fastq.gz	Fastqsanger.gz
	SRR060889.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 27

Similar Datasets

SAGE-Seq gene expression profiles of Hs578T, MCF7, and SUM159PT cells treated with STAT3 or non-targeting siRNAs, DMSO, or CXCR2, PTGIS, HAS1, PFKFB3, JAK, or NQO1 inhibitor

Project description:To investigate potential links between Stat3 transcriptional activity and other signaling pathways in breast cancer, we determined the gene expression profiles of three breast cancer cell lines treated with JAK, PTGIS, PFKFB3, CXCR2, HAS1, or NQO1 inhibitor (all of which decreased Stat3 transcriptional activity in Hs 578T cells except for the NQO1 inhibitor), inhibitor treatment vehicle alone (DMSO), STAT3 siRNAs, or non-targeting siRNAs. Using the resulting data, we identified a gene signature that was significantly regulated by STAT3 siRNAs and similarly affected by the JAK and at least 3 other inhibitors (or by 4 other inhibitors) but not by the NQO1 inhibitor in Hs 578T cells that was enriched in genes involved in development and correlated with shorter distant metastasis-free survival in primary lymph-node-negative invasive breast tumors. These results emphasize the central importance of Stat3 in CD44+/CD24- stem-cell-like breast cancer cells. This study includes SAGE-Seq libraries obtained using 27 samples that each underwent individual protocols. There are nine samples of each of three cell lines - Hs 578T, MCF7, and SUM159PT. The samples in each group were treated with either one of the six inhibitors, DMSO only (the background control for inhibitor-treated cells), STAT3 siRNAs, or non-targeting siRNAs (the background control for STAT3 siRNAs).

2011-09-08 | E-GEOD-22917 | biostudies-arrayexpress

SAGE-Seq gene expression profiles of Hs578T, MCF7, and SUM159PT cells treated with STAT3 or non-targeting siRNAs, DMSO, or CXCR2, PTGIS, HAS1, PFKFB3, JAK, or NQO1 inhibitor

2011-09-08 | GSE22917 | GEO

NQO1 regulates inflammatory signaling

Project description:NQO1 silencing by a specific shRNA against NQO1 increased migration and hormone-independent survival in hormone-dependent human prostate cancer cells LNCaP. Genome wide array revealed that NQO1 blockade significantly upregulated pro-inflammatory mediators (e.g., IL-32, CCL2, IL-8, IL-17C, IL-10RA, CXCR2, CXCR7, NOS3) associated with prostate tumorigenesis. Two-condition experiment, control vs. NQO1 knockdown LNCaP cells. Biological replicates: 3 control replicates, 3 NQO1 knockdown replicates.

2014-08-26 | E-GEOD-58336 | biostudies-arrayexpress

NQO1 regulates inflammatory signaling

2014-08-26 | GSE58336 | GEO

Effect of PARP1 inhibition on transcription high and low PARP activity cell lines

Project description:Analysis of the role of PARP1 in gene transcription in cell lines with variable PARP1 activity. Total RNA was collected from MCF7, KPL-1, ZR7530, T47D, SKBR3, and Hs578T cells that had been treated with 10uM ABT-888 or DMSO for 48 hours.

2014-09-04 | E-GEOD-58844 | biostudies-arrayexpress

Effect of PFKFB3 depletion on gene expression of primary murine vascular smooth muscle cells isolated from c57bl/6

Project description:To investigate the functional role of PFKFB3 in VSMCs osteogenic differentiation, we knockdowned PFKFB3 expression in VSMCs using siRNAs

2023-01-31 | GSE221995 | GEO

Folic acid induces cell type-specific changes in the transcriptomes of breast cancer cell lines

Project description:The effect of folic acid (FA) on breast cancer (BC) risk is uncertain. We hypothesised that this uncertainty may be due, in part, to differential effects of FA between BC cells with different phenotype. To test this we investigated the effect of treatment with FA concentrations within the range of unmetabolised FA reported in humans on the expression of the transcriptomes of non-transformed (MCF10a) and cancerous (MCF7 and Hs578T) BC cells. Total RNA obtained from three breast cancer cell lines (MCF10a, MCF7, Hs578T) treated with 100nmoles/l folic acid untreated control cells. Six replicates per treatment group.

2015-05-08 | E-GEOD-68651 | biostudies-arrayexpress

Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines

Project description:HCC1143, HCC70, HCC38, and SUM159PT cells were treated for 4 or 24 hrs with 1uM ruxolitinib. Control cells were treated for 24 hrs with DMSO (0.1%). The purpose was to determine changes in gene expresison patterns following inhibition of JAK1/2 in the cells.

2015-12-31 | GSE70508 | GEO

Effect of VIRMA amplification on gene expression in breast cancer cells

Project description:To confirm the contribution of elevated VIRMA levels towards cell proliferation and colony formation, we depleted VIRMA in four breast cancer cell lines, SKBR3, HS578T, MCF7 and MDAMB453 using short-hairpin RNAs (shRNAs). We then performed gene expression profiling analysis using data obtained from RNA-seq data

2023-08-03 | GSE205855 | GEO

Expression data from Jurkat cells treated with SB225002 for 6h and 9h.

Project description:In our efforts to evaluate the function of the IL-8 receptor CXCR2 in Acute Lymphoblastic Leukemia (ALL) cells, we made use of SB225002 (N-(2-hydroxy-4-nitrophenyl)-N’-(2-bromophenyl)urea), a drug initially described as a CXCR2 antagonist. Although the CXCR2 receptor was found to be non-functional in ALL, B- and T-ALL cell lines were sensitive to SB225002. We used microarray analysis to identify a transcriptional profile of genes that mediate SB225002's effects in acute lymphoblastic leukemia cells. Jurkat cells were treated for 6h or 9h with SB225002 [12.5 uM] or 0.1% DMSO (vehicle control).

2015-07-23 | E-GEOD-71212 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data